Palivizumab use in subjects with congenital heart disease: Results from the 2000-2004 Palivizumab Outcomes Registry

Pediatric Cardiology

Volumn 29, Issue 2, 2008, Pages 382-387

  Cohen, Stuart A ^a   Zanni, Robert ^b   Cohen, Alan ^c   Harrington, Molly ^d   Vanveldhuisen, Paul ^d   Boron, Marnie L ^e  

^a Primary Care Group   (United States)

^b MONMOUTH MEDICAL CENTER   (United States)

^c JAZZ PHARMACEUTICALS   (United States)

^d EMMES CORPORATION   (United States)

^e MEDIMMUNE   (United States)

Author keywords

Hospitalization; Prematurity; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; FEMALE; HEART DEFECTS, CONGENITAL; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; REGISTRIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 40949158908     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-007-9039-5     Document Type: Article

References (18)

1. Altman CA, Englund JA, Demmler G, et al. (2000) Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 21:433-438
2. American Academy of Pediatrics (1998) Committee on Infectious Disease and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102:1211-1216
3. American Academy of Pediatrics (2003) Committee on Infectious Disease and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112 (6 Pt 1):1442-1446
4. ®. 27th ed. American Academy of Pediatrics, Elk Grove Village, IL, pp 560-566
5. Boron M (2007) Case example 23: using registry data to study patterns of use and outcomes. In: Gliklich RE, Dreyer NA (eds) Registries for evaluating patient outcomes: a user's guide. Agency for Healthcare Research and Quality, Rockville, MD. http://effectivehealthcare.ahrq.gov/repFiles/Registries.pdf, April 2007
6. Feltes TF, Cabalka AK, Meissner HC, et al., for the Cardiac Synagis Study Group (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143:532-540
7. Hoffman JI, Kaplan S (2002) The incidence of congenital heart disease. J Am Coll Cardiol 39:1890-1900
8. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:530-537
9. Khongphatthanayothin A, Wong PC, Samara Y, et al. (1999) Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med 27:1974-1981
10. Leader S, Kohlhase K (2003) Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 143:S127-S132
11. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA (1982) Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 307:397-400
12. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC (1992) Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 20:1406-1413
13. Mullins JA, Lamonte AC, Bresee JS, Anderson LJ (2003) Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J 22:857-862
14. Navas L, Wang E, de Carvalho V, Robinson J, the Pediatric Investigators Collaborative Network on Infections in Canada (1992) Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 121:348-354
15. Palivizumab Outcomes Registry Study Group (2003) Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from the palivizumab outcomes registry. Pediatr Pulmonol 35:484-489
16. Romero JR (2003) Palivizumab prophylaxis of respiratory syncytial virus disease from 1998-2002: results from four years of palivizumab usage. Pediatr Infect Dis J 22:S46-S54
17. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ (1999) Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446
18. Terletskaia-Ladwig E, Enders G, Schalasta G, Enders M (2005) Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiology study. BMC Infect Dis 5:20